RT Journal Article
SR Electronic
T1 COVID-19 convalescent plasma to treat hospitalised COVID-19 patients with or without underlying immunodeficiency
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.08.09.22278329
DO 10.1101/2022.08.09.22278329
A1 Lacombe, Karine
A1 Hueso, Thomas
A1 Porcher, Raphael
A1 Mekinian, Arsène
A1 Chiarabini, Thibault
A1 Georgin-Lavialle, Sophie
A1 Ader, Florence
A1 Saison, Julien
A1 Blondel, Guillaume Martin
A1 De Castro, Nathalie
A1 Bonnet, Fabrice
A1 Cazanave, Charles
A1 François, Anne
A1 Morel, Pascal
A1 Hermine, Olivier
A1 Pourcher, Valérie
A1 Michel, Marc
A1 Lescure, Xavier
A1 Soussi, Nora
A1 Brun, Philippe
A1 Pommeret, Fanny
A1 Sellier, Pierre-Olivier
A1 Rousset, Stella
A1 Piroth, Lionel
A1 Michot, Jean-Marie
A1 Baron, Gabriel
A1 De Lamballerie, Xavier
A1 Mariette, Xavier
A1 Tharaux, Pierre-Louis
A1 Resche-Rigon, Matthieu
A1 Ravaud, Philippe
A1 Simon, Tabassome
A1 Tiberghien, Pierre
YR 2022
UL http://medrxiv.org/content/early/2022/10/27/2022.08.09.22278329.abstract
AB Efficacy of COVID-19 convalescent plasma (CCP) in COVID-19 pneumonia is uncertain. The CORIPLASM study was an open-label, Bayesian randomised clinical trial evaluating the efficacy of CCP in patients with moderate COVID-19, including immunocompromised patients. Patients hospitalised with COVID-19 and less than 9 days since symptoms onset were assigned to receive 4 units of plasma over 2 days (≈ 840 ml)(CCP) or usual care alone (UC). Primary outcomes were the proportion of patients with a WHO-Clinical Progression Score (CPS) ≥6 on the 10-point scale on day (d) 4 and survival without ventilation or additional immunomodulatory treatment by d14. A total of 120 patients were recruited and assigned to CCP (n=60) or UC (n=60), including 22 (CCP) and 27 (UC) immunocompromised patients. Thirteen (22%) patients with CCP had a WHO-CPS ≥6 at d4 versus 8 (13%) with UC, adjusted odds ratio (aOR) 1.88 [95%CI 0.71 to 5.24]. By d14, 19 (31.6%) patients with CCP and 20 (33.3%) patients with UC had ventilation, additional immunomodulatory treatment or had died. Cumulative incidence of death was 3 (5%) with CCP and 8 (13%) with UC at d14 (aHR 0.40 [95%CI 0·10 -1·53]), and 7 (12%) with CCP and 12 (20%) with UC at d28 (aHR 0.51 [95%CI 0.20-1.32]). Subgroup analysis indicated that CCP might be associated with a lower mortality in immunocompromised patients (HR 0.37 [95%CI 0.14-0.97]). CCP treatment did not improve early outcomes in patients with moderate COVID-19 but was associated with reduced mortality in the subgroup of immunocompromised patients.Competing Interest StatementPT, PM and AF are employees of Etablissement Francais du Sang (EFS), the French public transfusion service, which collects, manufactures, tests and issues all blood components in France. All other co-authors declare no competing interests related to the topic of the study.Clinical TrialClinicaltrials.gov Identifier: NCT04345991Funding StatementProgramme Hospitalier de recherche Clinique (DGOS-French Ministry of Health), Fondation pour la Recherche Medicale, Sorbonne Universite AAP 2020, Emergency Support Instrument (ESI), DG Sante, European Commission. A CC-BY public copyright license (CC-BY 4.0 https://creativecommons.org/licenses/by/4.0/) has been applied by the authors to the present document and will be applied to all subsequent versions up to the Author Accepted Manuscript arising from this submission, in accordance with the grant open access conditions.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical clearance was obtained from Comite de Protection des Personnes (CPP) Ile de France VI on April 10, 2020 (no. 26-20 Med.1)I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data for this article will be made available after publication on request from any qualified researchers or academicians. The data include: analysed deidentified participant data, data dictionary, study protocol, statistical analysis plan, and the informed consent form, among other data. The data will be shared for 2 years after publication upon receipt of a request sent to raphael.porcher@aphp.fr.